Navigation Links
PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
Date:10/16/2008

limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including ClinPhone; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008 as filed with the SEC on August 28, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward- looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trad
'/>"/>

SOURCE PAREXEL International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
2. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
3. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
4. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
5. PAREXEL Closes the Acquisition of ClinPhone
6. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
7. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
8. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
10. PAREXEL Expands Global Clinical Logistics Capabilities
11. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International ... that its wholly-owned subsidiary Renuell Int,l, Inc. has signed ... and Space Administration ("NASA") at the Johnson Space Center ... See photos: tapplic.com/houstonphotos/ ... are very pleased to announce our latest, exclusive agreement ...
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... 2, 2014  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, ... the appointment of Debra Zack , M.D., ... of Lloyd Rowland , senior vice president, ... "Debra,s expertise in biologics clinical development and ...
(Date:9/2/2014)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... targeting specific pathogens that cause serious infections and ... preclinical toxicology study of SYN-004. Per U.S. Food ... was required to move the Company,s lead anti-infective, ... effects of Clostridium difficile (C. difficile), ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... Micromet, Inc. (Nasdaq: ... for the treatment of cancer, inflammation and autoimmune diseases, ... Itin, will present at the Cowen Health Care Conference ... on Tuesday, March 17, 2009. A simultaneous webcast ...
... Company Receives Allowance of Patent Claims in the ... Highlighted in Nature Biotechnology -BRITISH COLUMBIA, Canada, March ... IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com ), a ... monoclonal antibodies based on its Dynamic Cross Linking ...
... Wis., March 6 Mach One Corporation (Pink ... subsidiary, Modular Process Constructors LLC, is changing its ... vision, and announces that it received a contract ... consumer health company. The contract is for a ...
Cached Biology Technology:Micromet to Present at the Cowen Health Care Conference on March 17, 2009 2Micromet to Present at the Cowen Health Care Conference on March 17, 2009 3Micromet to Present at the Cowen Health Care Conference on March 17, 2009 4InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies 2InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies 3Mach One Subsidiary Modular Process Constructors LLC Changes Name to MPS BioPharm to Better Reflect its Vision 2
(Date:9/2/2014)... with the participation of the University of Granada has ... place in the Iberian Peninsula around the mid Holocene ... dust coming from the Sahara increased. The data came ... Alpine lake in Sierra Nevada (Granada) , This study, ... based on the sedimentation of atmospheric dust from the ...
(Date:9/2/2014)... ideal source of nutrition for infants and it ... evolution and civilizations of human beings. Unlike our ... of bacterial species, including some opportunistic pathogens of ... scientists and physicians. , Indeed, the existence of ... of co-evolutionary and co-adaptive interactions between the microbiome ...
(Date:9/2/2014)... 2014 A study published in the September ... American Academy of Child and Adolescent Psychiatry ... psychiatric diagnosis had an increased risk of developing ... Using data from the nationwide Danish registers, a ... Nielsen, Psychiatry, Aalborg University Hospital, Denmark, studied 48,299children ...
Breaking Biology News(10 mins):Scientists obtain new data on the weather 10,000 years ago from sediments of a lake in Sierra Nevada 2Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3Risk of diabetes in children and adolescents exposed to antipsychotics 2
... for many people with depression and anxiety disorders, and ... care providers, according to researchers who analyzed the results ... shown to have tremendous benefits for mental health," says ... Program at Southern Methodist University in Dallas. "The more ...
... at Ume University and the Sahlgrenska Academy at the University ... can be found in fish that have been swimming in ... found in higher concentrations in the blood of fish than ... this hormone can lead to infertility in fish. The ...
... neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve ... report that the defective protein responsible for the disease ... inside neurons. The study appears in the April 5 ... ( www.jcb.org ). SCA5 results from a faulty ...
Cached Biology News:Mental health providers should prescribe exercise more often for depression, anxiety 2Medicine residues may threaten fish reproduction 2Defective protein is a double hit for ataxia 2
... QRT-PCR Mixes are formulated for use in ... SYBR Green. One-step QRT-PCR mixes offer a ... The pipetting steps are minimised, making the ... ,The 2x ABsolute QRT-PCR Mix is supplied ...
... of environmental and pathophysiological stressful conditions trigger ... known as heat shock proteins (HSPs), more ... The Hsp90 family of proteins in ... beta, Grp94, and Trap-1 (Hsp75). It was ...
... bespoke, cost-effective solutions for complex protein processing and production ... experience to help you develop a solution to your ... , do ... transfer all methodology to your own ...
... The Schleicher & Schuell BioScience Arraying ... dedicated to custom protein and nucleic ... project teams, comprised of R&D, Engineering, ... closely with collaborators every step of ...
Biology Products: